Medical Crossfire: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden is organized by Healio.
Release Date: September 15, 2023
Expiration Date: September 15, 2024
Activity Overview:
The Medical Crossfire®, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirited discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the latest data regarding traditional and recently approved treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), with an eye on providing extended treatment intervals for patients. This lively discussion will help place new developments into a clinical context to help you optimize care for your patients with nAMD and DME.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Discuss the limitations of intravitreal anti-vascular endothelial growth factor (VEGF) therapies that are currently used to treat nAMD and DME.
• Summarize clinical trial data regarding both traditional and emerging agents used for the management of nAMD and DME.
• Create individualized treatment plans that utilize a treat-and-extend dosing strategy in appropriate patients with nAMD and DME.